Myriad Genetics Appoints Raj Jampa as Chief Technology Officer

Myriad Genetics Inc. (MYGN) named Raj Jampa as chief technology officer, effective June 2, 2026, the company said in a statement. Jampa will lead the genetic testing firm’s technology strategy and platform development as it seeks to expand its precision medicine capabilities. Jampa most recently held senior technology roles at healthcare and diagnostics companies, according to the statement. He will report directly to Chief Executive Officer Paul J. Diaz. The appointment fills a key leadership position as Myriad competes with rivals Exact Sciences and Guardant Health in the oncology and hereditary cancer screening market. Financial terms of the appointment were not disclosed.